Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum11244910.26442/20751753.2022.5.201922Review ArticleTopical issues of prevention of stomach cancer: A reviewUspenskiyYury P.<p>D. Sci. (Med.), Prof., Saint Petersburg State Pediatric Medical University, Pavlov First Saint Petersburg State Medical University</p>uspenskiy65@mail.ruhttps://orcid.org/0000-0001-6434-1267BaryshnikovaNatalia V.<p>Cand. Sci. (Med.), Assoc. Prof., Saint Petersburg State Pediatric Medical University, Pavlov First Saint Petersburg State Medical University, Institute of Experimental Medicine</p>baryshnikova_nv@mail.ruhttps://orcid.org/0000-0001-7429-0336KrasnovAlexey A.<p>D. Sci. (Med.), Herzen Russian State Pedagogical University</p>dr.krasnov_28@mail.ruhttps://orcid.org/0000-0002-8732-6390PetlenkoSergey V.<p>D. Sci. (Med.), Golikov Research Clinical Center of Toxicology</p>petlenko@mail.ruhttps://orcid.org/0000-0002-2752-4598ApryatinaVera A.<p>Cand. Sci. (Med.), Saint Petersburg Institute of Bioregulation and Gerontology</p>vera1577@mail.ruhttps://orcid.org/0000-0002-9819-6835Saint Petersburg State Pediatric Medical UniversityPavlov First Saint Petersburg State Medical UniversityInstitute of Experimental MedicineHerzen Russian State Pedagogical UniversityGolikov Research Clinical Center of ToxicologySaint Petersburg Institute of Bioregulation and Gerontology150520222453583640811202208112022Copyright © 2022, Consilium Medicum2022<p>Prevention of gastric cancer, both primary and secondary, is an extremely important component of the management of gastroenterological patients. The correct collection of anamnesis with an assessment of the hereditary (family) cancer risk, the action of risk factors (eating disorders, habitual/chronic intoxication, obesity, <em>Helicobacter pylori </em>infection, etc.), as well as the use of gastroprotectors (in particular, the drug Regastim Gastro), especially in persons with potentially precancerous the condition is chronic atrophic gastritis. According to the data of a double-blind placebo-controlled randomized study Regastim Gastro (active ingredient alpha-glutamyl tryptophan) in the treatment of chronic atrophic gastritis, it was found that this drug has a powerful anti-inflammatory effect and regenerative activity. Taking the drug Regastim Gastro, compared with placebo, statistically significantly contributed to a decrease in the number of inflammatory infiltration cells per 1 mm<sup>2</sup> of the gastric mucosa. Regastim Gastro decreases in eosinophilic (3 times) and neutrophilic (4 times) infiltration of the gastric mucosa and also reduced the number of macrophages, lymphocytes and plasmocytes. In addition to anti-inflammatory properties, the drug also had a pronounced regenerative effect. Taking of Regastim Gastro statistically significant (<em>p</em>=0.028) increases in the number of glands per 1 mm<sup>2</sup> of the gastric mucosa by 26.1% compared with the initial screening indicators. In the group of patients taking placebo, on the contrary, there was a further progression of the pathological process, accompanied by a decrease in the number of glands per 1 mm<sup>2</sup> of the gastric mucosa after the end of treatment in comparison with the initial indicators. After the course of therapy, the number of glands per 1 mm<sup>2</sup> of the gastric mucosa in patients taking the drug Regastim Gastro was statistically significantly higher in comparison with the results in the placebo group (<em>p</em>=0.013). After the course of Regastim Gastro, there was an improvement in acid production: a shift in the acidic side of the average pH value (1.6 times) and an increase in the value of the acidity index, both when compared with the initial values (5.4 times) and in comparison with the placebo group (2.9 times). The intake of Regastim Gastro to patients with gastritis, both <em>H. pylori </em>(+) and <em>H. pylori</em> (-) before the development of atrophy of the gastric mucosa can reduce the inflammatory factor, prevent the occurrence of atrophy and may have maximum anti-carcinogenic action.</p>atrophystomach cancergastroprotectorsalpha-glutamyl-tryptophanатрофиярак желудкагастропротекторыальфа-глутамил-триптофан[Первичная профилактика рака – первая линия обороны в противораковой борьбе. Режим доступа: https://rosoncoweb.ru/library/another/004.pdf. Ссылка активна на 09.09.2022 [Pervichnaia profilaktika raka – pervaia liniia oborony v protivorakovoi bor'be. Available at: https://rosoncoweb.ru/library/another/004.pdf. Accessed: 09.09.2022 (in Russian)].][Roser M, Ritchie H. Cancer. Available at: https://ourworldindata.org/cancer. Accessed: 09.09.2022.][Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect. 2009;15(11):971-6. DOI:10.1111/j.1469-0691.2009.03031.x][Бордин Д.С. Рак желудка: на что обратить внимание врачу первичного звена? Лечащий врач. 2022. Режим доступа: https://www.lvrach.ru/articles/15438338?ysclid=l8blqxl25u937289776. Ссылка активна на 09.09.2022 [Bordin DS. Rak zheludka: na chto obratit' vnimanie vrachu pervichnogo zvena? Lechashchii vrach. 2022. Available at: https://www.lvrach.ru/articles/15438338?ysclid=l8blqxl25u93728977. Accessed: 09.09.2022 (in Russian)].][World Cancer Report. Available at: https://www.iarc.who.int/featured-news/new-world-cancer-report/ Accessed: 09.09.2022.][Заридзе Д.Г. Эпидемиология и этиология злокачественных заболеваний. Канцерогенез. М.: Научный мир, 2000, с. 26-30, 34-56 [Zaridze DG. Kantserogenez. Moscow: Nauchnyi mir, 2000, p. 26-30, 34-56 (in Russian)].][Копнин Б.П. Опухолевые супрессоры и мутаторные гены. Канцерогенез. М.: Научный мир, 2000, с. 86-87 [Kopnin BP. Opukholevye supressory i mutatornye geny. Kantserogenez. Moscow: Nauchnyi mir, 2000, p. 86-87 (in Russian)].][Черноусов А.Ф., Поликарпов С.А., Годжело Э.А. Ранний рак и предопухолевые заболевания желудка. М.: ИздАТ, 2002 [Chernousov AF, Polikarpov SA, Godzhelo EA. Rannii rak i predopukholevye zabolevaniia zheludka. Moscow: IzdAT, 2002 (in Russian)].][Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3(4):219-25. DOI:10.1007/pl00011720][Сельчук В.Ю., Никулин М.П. Рак желудка. РМЖ. 2003;26:1441 [Sel'chuk VIu, Nikulin MP. Rak zheludka. RMZh. 2003;26:1441 (in Russian)].][Прохоров А.В., Лабунец И.Н., Короткевич П.Е., Гедревич З.Э. Рак желудка: учебно-методическое пособие. Минск: БГМУ, 2021 [Prokhorov AV, Labunets IN, Korotkevich PE, Gedrevich ZE. Rak zheludka: uchebno-metodicheskoe posobie. Minsk: BGMU, 2021 (in Russian)].][Peng WJ, Jia XJ, Wei BG, et al. Stomach cancer mortality among workers exposed to asbestos: a meta-analysis. J Cancer Res Clin Oncol. 2015;141(7):1141-9. DOI:10.1007/s00432-014-1791-3][Welling R, Beaumont JJ, Petersen SJ, et al. Chromium VI and stomach cancer: a metaanalysis of the current epidemiological evidence. Occup Environ Med. 2015;72(2):151-9. DOI:10.1136/oemed-2014-102178][Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer. 2010;102(2):237-42. DOI:10.1038/sj.bjc.6605380][van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361-74. DOI:10.1136/jmedgenet-2015-103094][Lunet N, Valbuena C, Vieira AL, et al. Fruit and vegetable consumption and gastric cancer by location and histological type: case-control and meta-analysis. Eur J Cancer Prev. 2007;16(4):312-27. DOI:10.1097/01.cej.0000236255.95769.22][Huang Y, Chen H, Zhou L, et al. Association between green tea intake and risk of gastric cancer: a systematic review and dose-response meta-analysis of observational studies. Public Health Nutr. 2017;20(17):3183-92. DOI:10.1017/S1368980017002208][Kim SR, Kim K, Lee SA, et al. Effect of Red, Processed, and White Meat Consumption on the Risk of Gastric Cancer: An Overall and Dose-Response Meta-Analysis. Nutrients. 2019;11(4):826. DOI:10.3390/nu11040826][Buckland G, Travier N, Huerta JM, et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer. 2015;137(3):598-606. DOI:10.1002/ijc.29411][Fang X, Wei J, He X, et al. Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. 2015;51(18):2820-32. DOI:10.1016/j.ejca.2015.09.010][Ferro A, Rosato V, Rota M, et al. Meat intake and risk of gastric cancer in the Stomach cancer Pooling (StoP) project. Int J Cancer. 2020;147(1):45-55. DOI:10.1002/ijc.32707][González CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(5):345-54. DOI:10.1093/jnci/djj071][Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739. DOI:10.1136/bmjopen-2017-017739][Cheung KS, Chan EW, Wong AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28-35. DOI:10.1136/gutjnl-2017-314605][Suissa S, Suissa A. Proton-pump inhibitors and increased gastric cancer risk: time-related biases. Gut. 2018;67(12):2228-9. DOI:10.1136/gutjnl-2017-315729][Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut. 1991;32(6):698-701. DOI:10.1136/gut.32.6.698][Berlin RG. Omeprazole. Gastrin and gastric endocrine cell data from clinical studies. Dig Dis Sci. 1991;36(2):129-36. DOI:10.1007/BF01300745][Kidd M, Tang LH, Modlin IM, et al. Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a mastomys rodent model of gastric neoplasia. Digestion. 2000;62(2-3):143-51. DOI:10.1159/000007806][Ho AC, Horton KM, Fishman EK. Gastric carcinoid tumors as a consequence of chronic hypergastrinemia: spiral CT findings. Clin Imaging. 2000;24(4):200-3. DOI:10.1016/s0899-7071(00)00199-6][Henwood M, Clarke PA, Smith AM, Watson SA. Expression of gastrin in developing gastric adenocarcinoma. Br J Surg. 2001;88(4):564-8. DOI:10.1046/j.1365-2168.2001.01716.x][Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: their production and biological activities. Annu Rev Physiol. 2001;63:119-39. DOI:10.1146/annurev.physiol.63.1.119][Риск развития злокачественных новообразований у больных, получающих ингибиторы протонной помпы. Режим доступа: https://rosoncoweb.ru/news/oncology/2016/01/27/ Ссылка активна на 09.09.2022 [Risk razvitiia zlokachestvennykh novoobrazovanii u bol'nykh, poluchaiushchikh ingibitory protonnoi pompy. Available at: https://rosoncoweb.ru/news/oncology/2016/01/27/ Accessed: 09.09.2022 (in Russian)].][Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334(16):1018-22. DOI:10.1056/NEJM199604183341603][Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5(4):206-14. DOI:10.1046/j.1523-5378.2000.00032.x][Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006;23(5):639-47. DOI:10.1111/j.1365-2036.2006.02792.x][González CA, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer. 2003;107(4):629-34. DOI:10.1002/ijc.11426][IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 83: Tobacco Smoke and Involuntary Smoking. Lyon: International Agency for Research on Cancer, 2004. Available at: https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono83-1.pdf. Accessed: 09.09.2022.][Rota M, Pelucchi C, Bertuccio P, et al. Alcohol consumption and gastric cancer risk-A pooled analysis within the StoP project consortium. Int J Cancer. 2017;141(10):1950-62. DOI:10.1002/ijc.30891][Ma K, Baloch Z, He TT, Xia X. Alcohol Consumption and Gastric Cancer Risk: A Meta-Analysis. Med Sci Monit. 2017;23:238-46. DOI:10.12659/msm.899423][Tavakoli A, Monavari SH, Solaymani Mohammadi F, et al. Association between Epstein–Barr virus infection and gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):493. DOI:10.1186/s12885-020-07013-x][Cárdenas-Mondragón MG, Torres J, Flores-Luna L, et al. Case–control study of Epstein–Barr virus and Helicobacter pylori serology in Latin American patients with gastric disease. Br J Cancer. 2015;112(12):1866-73. DOI:10.1038/bjc.2015.175][Dávila-Collado R, Jarquín-Durán O, Dong LT, Espinoza JL. Epstein–Barr Virus and Helicobacter Pylori Co-Infection in Non-Malignant Gastroduodenal Disorders. Pathogens. 2020;9(2):104. DOI:10.3390/pathogens9020104][Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;gutjnl-2022-327745. DOI:10.1136/gutjnl-2022-327745][Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19(Suppl. 1):S37-43.][Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211-7. DOI:10.1016/j.gtc.2013.01.002][de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15. DOI:10.1016/S1470-2045(12)70137-7][Ekström AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121(4):784-91. DOI:10.1053/gast.2001.27999][Mitchell H, English DR, Elliott F, et al. Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer. Aliment Pharmacol Ther. 2008;28(7):903-10. DOI:10.1111/j.1365-2036.2008.03792.x][Brenner H, Arndt V, Stegmaier C, et al. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol. 2004;159(3):252-8. DOI:10.1093/aje/kwh039][Shakeri R, Malekzadeh R, Nasrollahzadeh D, et al. Multiplex H. pylori Serology and Risk of Gastric Cardia and Noncardia Adenocarcinomas. Cancer Res. 2015;75(22):4876-83. DOI:10.1158/0008-5472.CAN-15-0556][Simán JH, Engstrand L, Berglund G, et al. Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol. 2007;42(8):933-40. DOI:10.1080/00365520601173863][Kong YJ, Yi HG, Dai JC, Wei MX. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2014;20(19):5903-11. DOI:10.3748/wjg.v20.i19.5903][Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166-75. DOI:10.1007/s10120-015-0462-7][Ивашкин В.Т., Маев И.В., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70 [Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70 (in Russian)]. DOI:10.22416/1382-4376-2018-28-1-55-70][Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И., и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017;2:3-21 [Lazebnik LB, Tkachenko EI, Abdulganiyeva DI, et al. VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter Pylori-Associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;2:3-21 (in Russian)].][Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. DOI:10.1136/gutjnl-2015-309252][Kodama M, Murakami K, Okimoto T, et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion. 2012;85(2):126-30. DOI:10.1159/000334684][Poorolajal J, Moradi L, Mohammadi Y, et al. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiol Health. 2020;42:e2020004. DOI:10.4178/epih.e2020004][Li Q, Zhang J, Zhou Y, Qiao L. Obesity and gastric cancer. Front Biosci (Landmark Ed). 2012;17(7):2383-90. DOI:10.2741/4059][Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011;1229:45-52. DOI:10.1111/j.1749-6632.2011.06096.x][Mohammadi M. Role of Obesity in the Tumorigenesis of Gastric Cancer. Int J Prev Med. 2020;11:148. DOI:10.4103/ijpvm.IJPVM_153_19][Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010;28(26):4058-65. DOI:10.1200/JCO.2010.27.9935][Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes. 2020;11(5):1220-30. DOI:10.1080/19490976.2020.1762520][Dai D, Yang Y, Yu J, et al. Interactions between gastric microbiota and metabolites in gastric cancer. Cell Death Dis. 2021;12(12):1104. DOI:10.1038/s41419-021-04396-y][Bessède E, Mégraud F. Microbiota and gastric cancer. Semin Cancer Biol. 2022;86(Pt. 3):11-7. DOI:10.1016/j.semcancer.2022.05.001][Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4:4202. DOI:10.1038/srep04202][Eun CS, Kim BK, Han DS, et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter. 2014;19(6):407-16. DOI:10.1111/hel.12145][Castaño-Rodríguez N, Goh KL, Fock KM, et al. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep. 2017;7(1):15957. DOI:10.1038/s41598-017-16289-2][Sonveaux P, Copetti T, De Saedeleer CJ, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One. 2012;7(3):e33418. DOI:10.1371/journal.pone.0033418][Berry D, Reinisch W. Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol. 2013;27(1):47-58. DOI:10.1016/j.bpg.2013.03.005][Wang L, Zhou J, Xin Y, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016;28(3):261-6. DOI:10.1097/MEG.0000000000000542][Бакулин И.Г., Пирогов С.С., Бакулина Н.В., и др. Профилактика и ранняя диагностика рака желудка. Доказательная гастроэнтерология. 2018;7(2):44-58 [Bakulin IG, Pirogov SS, Bakulina NV, et al. Prophylaxis and early diagnosis of stomach cancer. Dokazatel'naya gastroenterologiya. 2018;7(2):44-58 (in Russian)]. DOI:10.17116/dokgastro201872244][Sugano K. Screening of gastric cancer in Asia. Best Pract Res Clin Gastroenterol. 2015;29(6):895-905. DOI:10.1016/j.bpg.2015.09.013][Lee S, Jun JK, Suh M, et al. Gastric cancer screening uptake trends in Korea: results for the National Cancer Screening Program from 2002 to 2011: a prospective cross-sectional study. Medicine (Baltimore). 2015;94(8):e533. DOI:10.1097/MD.0000000000000533][Kim GH, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointest Endosc. 2016;84(1):18-28. DOI:10.1016/j.gie.2016.02.028][Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. DOI:10.1586/egh.10.25][Haruma K, Ito M. Review article: clinical significance of mucosal- protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18(Suppl. 1):153-9. DOI:10.1046/j.1365-2036.18. s1.17.x][Hayashi S, Sugiyama T, Amano K, et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-9. DOI:10.1128/AAC.42.8.1895][Haruma K, Ito M, Kido S, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862-7. DOI:10.1023/a:1014716822702][Kamada T, Sato M, Tokutomi T, et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. DOI:10.1155/2015/865146][Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8. DOI:10.1136/gutjnl-2015-311019][Барышникова Н.В., Ткаченко Е.И., Успенский Ю.П. Оптимизация лечения больных с заболеваниями, ассоциированными с инфекцией Helicobacter pylori: обоснование необходимости использования препаратов висмута. Экспериментальная и клиническая гастроэнтерология. 2009;6:116-21 [Baryshnikova NV, Uspenskiĭ IuP, Tkachenko EI. Optimization of treatment of patients with diseases associated with Helicobacter pylori infection: justifying of bismuth preparations using. Eksp Klin Gastroenterol. 2009;6:116-21 (in Russian)].][Парфенов А.И., Ручкина И.Н. Синдром раздраженного кишечника (рекомендации для практических врачей). М., 2008 [Parfenov AI, Ruchkina IN. Sindrom razdrazhennogo kishechnika (rekomendatsii dlya prakticheskikh vrachei). Moscow, 2008 (in Russian)].][Tulassay Z, Herszényi L. Gastric mucosal defense and cytoprotection. Best Pract Res Clin Gastroenterol. 2010;24(2):99-108. DOI:10.1016/j.bpg.2010.02.006][Bagchi D, McGinn TR, Ye X, et al. Mechanism of gastroprotection by bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells. Dig Dis Sci. 1999;44(12):2419-28. DOI:10.1023/a:1026618501729][Кононов А.В., Мозговой С.И., Рыбкина Л.Б., и др. Оценка цитопротективного влияния висмута трикалия дицитрата на слизистую оболочку желудка при эрадикации H. pylori и пролонгированном приеме препарата. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2014;24(5):21-8 [Kononov AV, Mozgovoi SI, Rybkina LB, et al. Otsenka tsitoprotektivnogo vliianiia vismuta trikaliia ditsitrata na slizistuiu obolochku zheludka pri eradikatsii H. pylori i prolongirovannom prieme preparata. Rossiiskii zhurnal gastroenterologii, gepatologii i koloproktologii. 2014;24(5):21-8 (in Russian)].][Петленко И.С., Егорова Т.Ю., Петленко С.В., и др. Экспериментальное изучение специфической активности L-Глутамил-L-Триптофана. Современные проблемы науки и образования. 2019;3:175 [Petlenko IS, Egorova TY, Petlenko SV, et al. Experimental study of the specific activity of L-glutamyl- L-tryptophan. Sovremennye problemy nauki i obrazovaniya. 2019;3:175 (in Russian)].][Петленко С.В. Иммунная система человека в условиях химической опасности. Автореф. дис. ... д-ра мед. наук. СПб, 2007 [Petlenko SV. Immunnaya sistema cheloveka v usloviyakh khimicheskoi opasnosti. Avtoref. dis. ... d-ra med. nauk. Saint Petersburg, 2007 (in Russian)].][Петленко С.В., Иванов М.Б., Лось С.П., и др. Новый подход к интегральной оценке иммунной системы человека в условиях воздействия комплекса факторов химически опасных объектов. Medline.ru. Российский биомедицинский журнал. 2010;11:195-216 [Petlenko SV, Ivanov MB, Los SP, et al. The new approach to an integrates estimation of immune system of the person in conditions of influence of a complex of factors of objects of chemical hazard. Medline.ru. Rossiiskii biomeditsinskii zhurnal. 2010;11:195-216 (in Russian)].][Успенский Ю.П., Барышникова Н.В., Краснов А.А., и др. Влияние Регастим Гастро на восстановление кислотопродукции в желудке по данным суточной рН-метрии у больных хроническим атрофическим гастритом. Экспериментальная и клиническая гастроэнтерология. 2022;198(2):40-7 [Uspenskiy YuP, Baryshnikova NV, Krasnov AA, et al. The effectiveness of Regasthym Gastro in restoring acid production in the stomach according to daily pH-metry in patients with chronic atrophic gastritis. Experimental and Clinical Gastroenterology. 2022;198(2):40-7 (in Russian)]. DOI:10.31146/1682-8658-ecg-198-2-40-47]